一分钟看懂
这是一项关于尿路上皮癌的II 期研究，登记的药物或干预包括Gemcitabine；Carboplatin，当前状态为招募中。登记地点显示中国Philadelphia有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Gemcitabine；Carboplatin · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fox Chase Cancer Center · Philadelphia
- Temple University Hospital at Broad Street · Philadelphia
公开的入选条件
- * Patients must have metastatic or locally advanced histologically and radiographically confirmed urothelial carcinoma
- * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v1.1
- * Patients must have received treatment with enfortumab vedotin plus pembrolizumab in the first line setting. Study treatment may be started within 28 days of last treatment with EV-P or with continuing toxicities if considered by the Sponsor-Investigator to b
- * Age \> 18 years.
- * Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- * Patients must have normal organ and marrow function as defined below.
- Absolute neutrophil count \> 1,000/mm3 unless patient has constitutional neutropenia
- Platelets \> 80,000/ul
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07043972；登记信息更新于 2026-09-17。